Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 36185603)

  • 1. Safety and efficacy of peptide receptor radionuclide therapy with
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
    Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
    Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of
    Liu Q; Zang J; Sui H; Ren J; Guo H; Wang H; Wang R; Jacobson O; Zhang J; Cheng Y; Zhu Z; Chen X
    J Nucl Med; 2021 Mar; 62(3):386-392. PubMed ID: 32826319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
    Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
    Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
    Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
    Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
    [No Abstract]   [Full Text] [Related]  

  • 7. First-in-Humans Study of the SSTR Antagonist
    Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
    J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of indigenous
    Sitani K; Parghane RV; Talole S; Basu S
    Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
    Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage PRRT with
    Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
    BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of
    Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
    J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
    Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of
    Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
    Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy, toxicity and survival of salvage retreatment PRRT with
    Sitani K; Parghane R; Talole S; Basu S
    Br J Radiol; 2022 Sep; 95(1137):20210896. PubMed ID: 35816545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
    Shin Y; Moon BH; Ryoo BY; Chang HM; Kim KP; Hong YS; Kim TW; Ryu JS; Kim YI; Yoo C
    Target Oncol; 2024 Jan; 19(1):41-49. PubMed ID: 38108953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
    Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
    Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
    Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.